![](https://www.elaia.com/wp-content/uploads/2024/05/HEPHAISTOS_logo_large.png)
Therapies against incurable and metastatic cancers.
Entrepreneurs
Frédéric Caroff
Martine Caroff
Elaia Team
Florian Denis
Related articles
![](https://www.elaia.com/wp-content/uploads/2024/05/3V7A6018.png)
HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq.
2024.05.16 / 3min read.